p53 limits the proliferation of primary diploid fibroblasts by inducing a state of growth arrest named replicative senescence -a process which protects against oncogenic transformation and requires integrity of the p53 tumour suppressor pathway [1] [2] [3] . However, little is known about the downstream target genes of p53 in this growth-limiting response. Here, we report that suppression of the p53 target gene encoding plasminogen activator inhibitor-1 (PAI-1) by RNA interference (RNAi) leads to escape from replicative senescence both in primary mouse embryo fibroblasts and primary human BJ fibroblasts. PAI-1 knockdown results in sustained activation of the PI(3)K-PKB-GSK3β pathway and nuclear retention of cyclin D1, consistent with a role for PAI-1 in regulating growth factor signalling. In agreement with this, we find that the PI(3)K-PKB-GSK3β-cyclin D1 pathway is also causally involved in cellular senescence. Conversely, ectopic expression of PAI-1 in proliferating p53-deficient murine or human fibroblasts induces a phenotype displaying all the hallmarks of replicative senescence. Our data indicate that PAI-1 is not merely a marker of senescence, but is both necessary and sufficient for the induction of replicative senescence downstream of p53.
-p53 tumour suppressor pathway during prolonged culturing in vitro, which induces a postmitotic state referred to as replicative senescence. Senescence can be overcome by loss of either p19 ARF , p53 or the combined loss of all three retinoblastoma family proteins 1, 2 . Proliferation of fibroblasts is induced by growth factors which activate cyclin-dependent kinases (CDKs), and in turn inactivate pRb's growth-limiting ability 2 , a G1 cell-cycle checkpoint that is often deregulated in cancer 3 . It is unclear which of the many downstream p53-target genes is responsible for the p53-dependent induction of replicative senescence. An attractive candidate is the CDK inhibitor p21 CIP1 . However, mouse embryo fibroblasts (MEFs) knocked out for p21 CIP1 are not immortal 4 . Here, we identify an unexpected causal role for the urokinase type plasminogen activator (uPA)-PAI-1 system in the induction of replicative senescence. The serpin and extra-cellular matrix (ECM)-associated protein PAI-1 is a direct target of p53 (ref. 5, 6) , is upregulated in ageing fibroblasts in vivo and in vitro, and is considered a marker of replicative senescence [7] [8] [9] . PAI-1 inhibits the activity of the secreted protease uPA by forming a stable complex. uPA expression can cause cells to progress through G1 into S phase 10 , most likely through activating a mitogenic signalling cascade by increasing the bioavailability of growth factors.
To investigate the role of PAI-1 in replicative senescence, two independent retroviral vectors were generated that targeted murine PAI-1 for suppression through RNAi 11 . When primary MEFs were infected with either PAI-1 knockdown (kd) construct (PAI-1 kd I or PAI-1 kd II), bypass of senescence was observed in a colony formation assay (Fig. 1a) . As inhibition of PAI-1 expression leads to activation of uPA 12, 13 , we asked whether overexpression of uPA also caused immortalisation. Retrovirusmediated over-expression of pro-uPA was as efficient as PAI-1 knockdown in causing immortalisation of MEFs (Fig. 1a) . To assess PAI-1 levels in infected MEFs, p53 kd , PAI-1 kd or uPA overexpressing cells were serially passaged until they had become post-senescent at passage 9 (P9) (that is, when control MEFs were senescent) and observed a significant reduction in PAI-1 mRNA expression in PAI -1 kd MEFs by quantitative RT-PCR (QRT-PCR; Fig. 1b ). As PAI-1 is a transcriptional p53 target 5, 6 and p53 is activated during replicative senescence, PAI-1 is highly expressed in senescent MEFs 9 . Accordingly, P9 MEFs expressed more PAI-1 than P3 or p53 kd cells, which had comparable PAI-1 mRNA levels (Fig. 1b) . uPA activity is downstream of PAI-1 and p53, and consequently immortal cells overexpressing uPA have PAI-1 expression levels similar to those observed in P9 MEFs (Fig. 1b) . When examined in a long-term cell proliferation assay, PAI-1 kd also extended the proliferative capacity of MEFs far beyond that of wild-type cells (see Supplementary  Information, Fig. S1a (Fig. 1c) . Importantly, six independent immortal PAI-1 -/-MEF cell lines showed normal p53 function after DNA-damage exposure (Fig. 1d) .
Next, we sought to understand the molecular pathway(s) involved in the immortalisation of MEFs after PAI-1 knockdown or uPA overexpression. The tumour suppressors p16 INK4A and p21 CIP1 were induced in P9 MEFs and immortal PAI-1 kd or uPA overexpressing cells, indicating that the senescence-stress pathway is activated in these MEFs (Fig. 2a) . Interestingly, a sharp increase in cyclin D1 levels were observed in both non-proliferating P9 and proliferating PAI-1 kd or uPA overexpressing MEFs, which may neutralize the high levels of p21 CIP1 (Fig. 2a) . We asked whether signalling through PI(3)K, PKB (also known as AKT) and GSK3β was involved. Activation of PI(3)K and subsequent full activation of PKB by phosphorylation on Ser 473 leads to an inhibitory phosphorylation of GSK3β on Ser 9 by PKB 17, 18 . GSK3β controls cyclin D1 localization and degradation through an inhibitory phosphorylation on Thr 286 and loss of this inhibitory phosphorylation protects cyclin D1 from nuclear exclusion and degradation 19 . Therefore, mitogenic signalling through PI(3)K-PKB-GSK3β influences cyclin D1 stability and its nuclear activity, leading to cell-cycle progression 2 . uPA induces growth factor-related PI(3)K-PKB signalling 20 and, as a result, uPA activity may result in nuclear retention of cyclin D1 by inducing loss of GSK3β activity through phosphorylation on Ser 9. When cyclin D1 localization was determined in ageing MEFs, a striking but gradual nuclear exclusion of cyclin D1 was observed (Fig. 2b ), which correlated with the decline in growth rate (note that wild-type MEFs became fully senescent at passage 8; see Supplementary Information, Fig. S2a , as confirmed by staining for senescence-associated acidic β-galactosidase 21 , SA-β-Gal; data not shown). Furthermore, during serial passaging, wild-type MEFs show a progressive decline in PKB activation by loss of phosphorylation and a gradually increased GSK3β activation by loss of inhibitory phosphorylation (Fig. 2c) . In contrast, immortal PAI-1 kd or uPA overexpressing MEFs had sustained PKB-GSK3β signalling (see Supplementary Information,  Fig. S2b ). We therefore concluded that during replicative senescence cyclin D1 is excluded from the nucleus and stabilized in the cytosol, correlating with decreased growth-rate and downregulation of PKB-GSK3β signalling. The high levels of cyclin D1 found in senescent cells (Fig. 2a) were unexpected because GSK3β activity induces not only nuclear exclusion, but also the turnover of cyclin D1 (ref. 19) . Significantly, high levels of cyclin D1 were also observed in senescent human BJ fibroblasts (Fig. 5c) . Apparently, the turnover of cyclin D1 is different in senescent cells as compared with cycling NIH3T3 cells 19 . We next examined whether immortalisation of MEFs by PAI-1 knockdown may be the result of activated PI(3)K-PKB-GSK3β signalling. Primary MEFs were retrovirally transduced with constitutively active mutants of PI(3)K (p110α CAAX ; Ca-PI(3)K) or PKB (Myr-PKB; Ca-PKB), a retroviral knockdown short hairpin RNA (shRNA) construct for GSK3β, or retroviral expression constructs for wild-type cyclin D1 (D1) or nondegradable cyclin D1 (T286A-cyclin D1; TA-D1), and determined their immortalizing potential in a colony-formation assay. The TA-D1 mutant is refractory to phosphorylation by GSK3β and is therefore constitutively nuclear 19 . We found that Ca-PI(3)K, Ca-PKB, GSK3β kd or TA-D1 (but not wild type D1) are individually capable of immortalizing wild-type MEFs (Fig. 3a) . Furthermore, no loss of p19 ARF expression or evidence for mutation of p53 was found in any of the immortalised MEFs (data not shown). When tested in a long-term proliferation assay, overexpression of Ca-PI(3)K, Ca-PKB, GSK3β kd or TA-D1 (but not wild type D1) also induced a bypass of senescence in MEFs (Fig. 3b) . Again, immortalisation was not accompanied by loss of p19 ARF or p53 function (data not shown). As previously observed in PAI-1 kd or uPA overexpressing MEFs (Fig. 2a) , induction of p21 CIP1 protein levels in the post-senescent polyclonal cell lines expressing a Ca-PI ( To examine whether reduction of PI(3)K-PKB-GSK3β signalling is sufficient for the induction of senescence, antagonists of this mitogenic signalling route were overexpressed in p53-depleted cells. Retroviral cDNA expression constructs were generated for human PAI-1 (which is not targeted by the mouse PAI-1 kd vectors), mouse PTEN and GSK3β. PTEN is a potent tumour suppressor often deleted in cancer that blocks the activation of PI(3)K 22 and exerts its effect in part by regulating nuclear availability of cyclin D1 (ref. 23) . When overexpressed in p53 kd or PAI-1 kd cells, PAI-1, PTEN and GSK3β were all individually able to induce senescence, as observed by a flat-cell morphology and positive staining for SA-β-Gal. (Fig. 4a-d ). To test whether cyclin D1 is an essential target downstream of PAI-1, PAI-1 was overexpressed in p53 -/-MEFs, MEFs overexpressing TA-D1, or pocket-protein deficient triple knockout cells (pRb
; TKO). The immortal TKO controls lack retinoblastoma family function and therefore have sustained E2F activity 24, 25 . In normal fibroblasts pRb (family)-E2F-mediated repression is required for cell-cycle exit in response to p19 ARF -p53 activation 26 . Overexpression of TA-D1 in MEFs may therefore resemble the phenotype seen in TKO cells by blocking retinoblastoma family function. Figure 4e shows that PAI-1 induced an arrest in p53 -/-cells, but not when these cells also expressed TA-D1 or were pocket-protein deficient. These results suggest that in the presence of a wild-type cyclin D1 protein, PAI-1 is able to induce an arrest, but not when cyclin D1 is constitutively nuclear and insensitive to GSK3β.
The senescence response of human fibroblasts is, in the first instance, primarily dependent on p53 (M1 checkpoint) and, as in MEFs, PAI-1 is upregulated during ageing and is a marker of senescence in these cells 7, 27 . When primary human BJ fibroblasts were infected with either one of two independent human-specific PAI-1 knockdown constructs (PAI-1 kd I or PAI-1 kd II) an M1 senescence-bypass was observed as judged in a long-term growth assay (Fig. 5a) . As in MEFs, overexpression of uPA also induced a bypass of senescence in primary BJ cells, albeit with lower efficiency (Fig. 5a ). When the post-senescent and proliferating population doubling (PD) 68 PAI-1 kd were assayed for PAI-1 levels, reduction to levels even below those observed in young PD 30 BJ fibroblasts was observed (Fig. 5b) . PAI-1 levels in PD 68 uPA overexpressing BJ cells were similar to those seen in senescent cells, in agreement with the notion that uPA acts downstream of p53. PAI-1 kd or uPA overexpressing fibroblasts have notably higher levels of p21 CIP1 than p53 kd cells (Fig. 5b, c) , consistent with the notion that PAI-1 kd mediates senescence-bypass downstream of p53. That p53 is wild type in the PAI-1 kd or uPA over-expressing BJ fibroblast is also supported by their normal response to DNA damage (data not shown). As observed in MEFs, induction of cyclin D1 in PAI-1 kd and uPA overexpressing post-senescent BJ cells, as well as in non-proliferating senescent BJ cells, was observed (Fig. 5c) . Furthermore, an increase in cytoplasmic cyclin D1 in ageing BJ fibroblasts was noticed, which was associated with p21 CIP1 (see Supplementary Information, Fig. S4a-c) , although the nuclear-to-cytoplasmic transition of cyclin D1 seems to be not as pronounced as in ageing MEFs. Importantly, overexpression of murine PAI-1, PTEN, or GSK3β in immortal human p53 kd or PAI-1 kd cells induced an arrest and SA-β-Gal. staining (Fig. 5d, e) , indicating that PAI-1 expression and downregulation of the PI(3)K-PKB-GSK3β signalling route are also sufficient for induction of senescence in human fibroblasts downstream of p53 and PAI-1. Taken together, we conclude that PAI-1 is necessary and sufficient for senescence in human BJ fibroblasts. As p21 CIP1 is an essential p53 target in the senescence response of human fibroblasts 28, 29 , we asked if simultaneous knockdown of both p21 CIP1 and PAI-1 would induce a more efficient bypass of senescence than either one alone. Knockdown of the expression of either PAI-1 or p21 CIP1 resulted in a less efficient senescence-bypass than observed with knockdown of p53 (see Supplementary Information, Fig. 5a, b) . Interestingly, simultaneous knockdown of PAI-1 and p21 CIP1 resulted in a more efficient bypass of the arrest than knockdown of p53 itself (see Supplementary Information,  Fig. S5a−c) . We conclude that PAI-1 and p21 CIP1 are both relevant downstream targets of p53 in the induction of senescence in human fibroblasts, as evident from the effects of their combined knockdown. Here, we show that PAI-1 is a critical downstream target of p53 in the senescence response of both ageing mouse and human diploid fibroblasts. Our data indicate that p53 controls growth factor-dependent proliferation by upregulating PAI-1, leading to down-regulation of PI(3)K-PKB signalling and nuclear exclusion of cyclin D1. Conversely, we found that loss of PAI-1 expression or uPA overexpression in MEFs conferred resistance to the anti-proliferative activity of p53 by inducing sustained PI(3)K-PKB signalling and cyclin D1 nuclear retention. Our data are consistent with a model in which PAI-1 acts to limit cyclin-CDK activity during the induction of replicative senescence and suggest a role for PAI-1 as a secreted gatekeeper of fibroblast proliferative capacity (Fig. 5f) .
MEFs control MEFs
We found that the mitogen-stimulated PI(3)K-PKB pathway is causally involved in the senescence-bypass of fibroblasts, and that overexpression of its antagonist, PTEN 22 , can reverse this process. It has been reported that the levels of PTEN are crucial in determining the senescence response of fibroblasts -partial loss of PTEN confers a proliferative advantage, whereas acute loss of all PTEN induces senescence 30 . Consistent with this, we found that somatic knockdown of PTEN in wild-type MEFs resulted in bypass of senescence (data not shown) and constitutive activation of the PI(3)K-PKB signalling route, albeit not to the degree seen in Ca-PI(3)K or Ca-PKB overexpressing cells (see Supplementary Information,  Fig. S3b ). In apparent conflict with our data, which show senescence bypass by active PKB, it has been reported that overexpression of an active PKB resulted in induction of senescence. However, when these cells were followed over 6 days, proliferation was not entirely lost in the infected population 30 . We have selected PKB-infected wild type MEFs over a longer period of time, and consequently enriched for proliferating cells with potentially only moderately enhanced PKB activity. Taken together, these data support the notion that slightly elevated levels of PKB or partial loss of PTEN results in enhanced proliferation, whereas highly elevated PKB or complete loss of PTEN induces senescence. This is reminiscent of what has been observed in RAS signalling, where overexpression of an activated RAS oncogene induces senescence, whereas activated RAS expressed at physiological levels confers a growth advantage 31 . PAI-1 is induced by a variety of growth factors and is a target of cMyc 7, 32 . uPA transcription and its extracellular activity are regulated by growth-factor signalling and proteases. Induction of PAI-1 may therefore be part of a growth factor-stimulated negative feedback loop that becomes constitutively activated by p53 in ageing fibroblasts. As a consequence, senescent fibroblasts may induce a state of growth-factor unresponsiveness by secreting PAI-1. It is therefore possible that induction of PAI-1 by p53 or disturbance of the uPA or PAI-1 levels influences intra-tumour heterotypic signalling and the local tumour microenvironment. This is particularly noteworthy as uPA and PAI-1 are causally involved in wound healing, angiogenesis and metastasis 12, 33 -processes that are dominantly regulated by cell-cell signalling 34 . Furthermore, uPA is secreted by stromal fibroblasts and myofibroblasts at the invasive front in breast and prostate cancer 35 metastasis in mouse models 36, 37 . As it is becoming increasingly clear that stromal tissue is an indispensable player in neoplastic transformation and metastasis 38, 39 , our observations may lead to a better understanding of the role of fibroblasts in cancer.
METHODS

Antibodies and Vectors. For western blotting, antibodies against p16
CIP1 (F5, C19), SP1 (PEP2), cyclin D1 (H295, M20), cyclin E (M20), PCNA (PC-10), PKB-Akt1 (C20), p53 (DO-1), HA (Y11) and CDK4 (C22) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); anti p-PKB (Ser473; #9271), anti p-GSK3β (Ser9; #9336) and HSP90 (#4874) from Cell Signalling (Beverly, MA); anti p19 ARF (Ab 80-100) from Abcam (Cambridge, UK); anti-GSK3β (610201) from BD Pharmingen (San Jose, CA); anti phosphotyrosine (PY20) from Calbiochem (San Diego, CA); and anti p53 (Ab7) from Oncogene Research Products (Boston, MA). Flag-tagged mouse cDNAs for PAI-1, GSK3β, PTEN or human PAI-1 were generated by PCR amplification and cloned into pLZRS-IRES-zeocin. Mouse cDNA for uPA was generated by PCR amplification of pro-uPA and cloned into pBABEpuro. The production of siRNAs in MEFs, BJ or tsLT-hTERT-BJ fibroblasts was achieved using the pRETRO-SUPER vector 11 . For the generation of mouse PAI-1 knockdown constructs the following 19-mer sequences were used: PAI-1 I, 5′-GAACAAGAATGAGATCAGT-3′; PAI-1 II, 5′-GTTGGGCATGCCTGACATG-3′. For the generation of human PAI-1 knockdown constructs the following 19-mer sequences were used: PAI-1 I, 5′-CTGACTTCACGAGTCTTTC-3′; PAI-1 II, 5′-CCTGGGAATGACCGACATG-3′. The 19-mer sequences used for knockdown of mouse p53 or GSK3β have been described elsewhere 40, 41 , as have the 19-mer sequences used for knockdown of human p53 or p21 CIP1 (ref. 29) . Control infections were performed with nonfunctional hairpin or red fluorescent protein (RFP) vectors.
Cell culture, transfection and retroviral infection. MEFs, primary and tsLT hTERT human BJ fibroblasts and Phoenix cells were cultured in DMEM (Gibco, Carlsbad, CA) supplemented with 8% heat-inactivated fetal bovine serum (Perbo; PAA, Pasching, Austria), 2 mM l-glutamine and penicillin-streptomycin (Gibco). Transfections were performed with the calcium-phosphate precipitation technique. Retroviral supernatants were produced by transfection of Phoenix packaging cells. Viral supernatants were filtered through a 45 µm Millex HA filter (Millipore, Carrigtwohill, Ireland) and infections were performed in the presence of 4 µg ml -1 polybrene (Sigma, St Louis, MO). Drug selections in MEFs or BJs were performed with 1 µg ml -1 puromycin, 50 µg ml -1 hygromycin or 100 µg ml -1 zeocin.
Colony-formation assays. Wild-type MEFs were infected with shRNA or cDNA constructs at P3, selected and at P5 5 × 10 4 cells were seeded onto 10-cm plates and stained after 3 weeks. CIP1 during ageing in culture. PAI-1 antagonizes uPA-GF (growth factor) signalling to cyclin D1 through PI(3)K-PKB-GSK3β and p21
CIP1 blocks cyclin D1 activity directly. The PAI-1-cyclin D1 connection is dominant over p21 CIP1 activity and controls induction of the senescence response downstream of p53 and upstream of pRb.
p53
-/-or wild-type MEFs (1.5 × 10 5 ) were plated in a 6-cm dish at P1, and every 4 days cells were counted and 1.5 × 10 5 cells were replated. Human primary BJ fibroblasts at population-doubling 53 were infected, selected and 1.5 × 10 5 cells were plated in a 6-cm dish (time = 0 days). Every 4 days, cells were counted and 1.5 × 10 5 cells were replated. Human tsLT BJ fibroblasts were infected, shifted to 39 °C after 48 h and 1.5 × 10 5 cells were plated in a 6-cm dish (time = 0 days). Every 6 days, cells were counted and 1.5 × 10 5 cells were replated. The p53 status of control, senescent or post-senescent primary MEFs, BJ fibroblasts or tsLT BJ fibroblasts was checked by DNA-damage induced p53 activation by overnight addition of 0.5 mM cisplatin and western blotting for p53 and its targets (p19 Acidic β-galactosidase staining. p53 kd or PAI-1 kd MEFs were infected, after 4 days plated under low density (5 × 10 4 cells in a 10-cm plate) and 24 h later stained overnight for senescence-associated acidic β-galactosidase as previously described 21 . Human post-senescent immortal p53 kd or PAI-1 kd BJ fibroblasts were infected, after 5 days plated under low density (1 × 10 5 cells in a 10-cm plate), and 48 h later stained overnight for acidic β-galactosidase as previously described 21 . Per plate, three independent groups of 300 cells were counted for SA-β-Gal staining. For all SA-β-Gal stainings, representative examples of at least two independent experiments are shown. Images were obtained using a Zeiss Axiovert 25 microscope with A-Plan 10× or LD A-plan 20× objectives on a Canon Powershot G3 14× zoom camera.
Western blotting. Selected cells were lysed in RIPA buffer (50 mM Tris at pH 8, 150 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS). 20, 40 or 80 micrograms of Proteins (20, 40 or 80 µg) were separated by 8-12% SDS-PAGE and transferred to polyvinylidine difluoride membranes (Millipore, Billerica, MA). Western blots were probed with the indicated antibodies. For all western blots representative examples of at least two independent experiments are shown.
Coimmunoprecipitations. Total cell lysates were isolated with ELB buffer (0.25 M NaCl, 0.1% NP40, 50 mM HEPES at pH 7.3) supplemented with Complete protease inhibitors (Roche). Cytoplasmic fractions of BJ cells were isolated with nuclear and cytoplasmic extraction kit NE-PER (Pierce Biotechnology Inc., Rockford, IL) according to manufacturers' instructions. Lysates were incubated with protein-A−Sepharose beads (Amersham-Pharmacia Biotech, Piscataway, NJ) coated with anti-cyclin D1 (M20, Santa Cruz Biotechnology). Analysis of cyclin D1 or cyclin D1-associated proteins was performed by western blotting the precipitates from cytoplasmic and total lysates. Total cell number (log2) 
